EUVIMEDEUVIMED entdecken
Crossref

Odoratin balances ROS / NO through EZH2 / PPARγ signalling to improve myocardial fibrosis

Bin Rao, Min Zhang, Min Liu, Yan Tu

Clinical and Experimental Pharmacology and Physiology · 2024

DOI: 10.1111/1440-1681.70002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, 2024. Verfasst von Bin Rao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nanchang Medical College, Nanchang, China. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Fibrosis, PPAR gamma, Signal Transduction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Science and Technology Plan Project of Jiangxi Provincial Health Commission, Science and Technology Plan Project of Jiangxi Provincial Department of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myocardial fibrosis is a critical concern in clinical medicine. This study explores the potential of odoratin as a treatment for myocardial fibrosis and investigates its underlying mechanisms. In vitro experiments involved stimulating primary mouse cardiomyocytes with TGF‐β1, followed by odoratin treatment, to assess levels of reactive oxygen species (ROS) and nitric oxide (NO). In vivo, a mouse model of myocardial fibrosis was established using abdominal aortic constriction (AAC) and treated with odoratin. ROS and NO levels in myocardial tissue were then evaluated. Immunofluorescence and Western blotting analysis showed that odoratin reduced excess ROS, enhanced NO production and decreased fibrosis‐related protein expression in vitro. In vivo, odoratin significantly improved cardiac function, reduced ROS, increased NO levels and mitigated fibrosis in AAC‐induced mice. Both in vitro and in vivo, odoratin inhibited the expression of NADPH oxidase 4 and EZH2, while promoting the expression of phosphorylated endothelial nitric oxide synthase (p‐eNOS) and PPARγ. The anti‐fibrotic effects of odoratin were reversed by PPARγ antagonism, and EZH2 overexpression diminished PPARγ activation by odoratin. These findings suggest that odoratin may combat myocardial fibrosis by balancing ROS and NO through PPARγ activation, with EZH2 inhibition likely playing a key regulatory role.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reactive Oxygen SpeciesFibrosisPPAR gammaSignal TransductionNitric OxideEnhancer of Zeste Homolog 2 ProteinAnimalsMiceMaleMyocardiumMice, Inbred C57BLMyocytes, CardiacCardiomyopathiesNitric Oxide Synthase Type III

Stichwörter der Autor:innen

EZH2PPARγROS/NO balancemyocardial fibrosisodoratin

Substanzen

Reactive Oxygen SpeciesPPAR gammaNitric OxideEnhancer of Zeste Homolog 2 ProteinEzh2 protein, mouseNitric Oxide Synthase Type III

Autor:innen und Institutionen

  • Nanchang Medical College, Nanchang, China.
  • Jiangxi Health Vocational College, Nanchang, China.
  • Shangrao Health Vocational College, Shangrao, China.

Förderung

  • Science and Technology Plan Project of Jiangxi Provincial Health Commission
  • Science and Technology Plan Project of Jiangxi Provincial Department of Education

Zitieren

APA

Rao, B., Zhang, M., Liu, M., & Tu, Y. (2024). Odoratin balances ROS / NO through EZH2 / PPARγ signalling to improve myocardial fibrosis. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.70002

Vancouver

Rao B, Zhang M, Liu M, Tu Y. Odoratin balances ROS / NO through EZH2 / PPARγ signalling to improve myocardial fibrosis. Clinical and Experimental Pharmacology and Physiology. 2024. doi:10.1111/1440-1681.70002

BibTeX
@article{Rao2024,
  author = {Rao, Bin and Zhang, Min and Liu, Min and Tu, Yan},
  title = {Odoratin balances ROS / NO through EZH2 / PPARγ signalling to improve myocardial fibrosis},
  journal = {Clinical and Experimental Pharmacology and Physiology},
  year = {2024},
  doi = {10.1111/1440-1681.70002}
}
Kostenlos starten →